These developments represent a significant step forward in our collective mission to fight Alzheimer's disease and dementias. If these topics are relevant to your work, we would love to chat! Find out more here:

At AAIC25, we will be presenting the poster "Sensitivity of Cognitive Outcome Measures to Plasma p-tau217 in Mild Cognitive Impairment in the AI-Mind study," by Alex Kaula. Sign up to be the first to download this research:

Join millions who have switched to Grok.

Check out our latest research at #AAIC25. This poster presents comprehensive data on the development of composite speech biomarkers, rigorously validated for use as a novel endpoint in MCI/AD clinical trials. Find out more:

Speech biomarkers for MCI/AD - presenting analytical and clinical validation in Dutch, Danish, German & Spanish! Discover the impact of our global validation research presented at AAIC 2025. Dive deeper:

Ensuring Data Reliability in High-Frequency Remote Assessments: Sign up to be the first to receive our research and find out how we are building confidence in remote data collection: #AAIC2025 #DigitalBiomarkers #Alzheimers #Psychometrics #ClinicalTrials

We're thrilled to announce! We're presenting 4 exciting posters at #AAIC25! 🧠 Discover our latest science and get the insights shaping #CNS drug development: .#Alzheimers #DigitalBiomarkers #ClinicalTrials

We're looking forward to seeing you tomorrow at the Digital Biomarkers in Clinical Trials Summit! . #digitalbiomarkers #digitalhealth #clinicaltrials #cognition #pharmaceuticalresearch

Join us at 11:20am on 25th June to hear real world examples of how digital assessments can improve patient engagement. Register now to secure your place: #DigitalBiomarkers #ClinicalTrials #DigitalHealth #PharmaInnovation

We're looking forward to this key event for leaders and innovators in #digitalhealth and #pharmaceuticalresearch, exploring evolving role of #digitalbiomarkers in #clinicaltrials to drive the acceleration of drug development. Secure your spot:

Sponsored by Biogen in collaboration with Apple, he study enrolled a representative sample of 23,004 participants across the United States and relied on Cambridge Cognition's CANTAB® platform for the core cognitive assessment. Read more here:

Michael Spilka shares his key takeaways from this year's #Schizophrenia International Research Society Congress, and the key findings on his poster presentations. Read more:

ICYMI: Stay up-to-date on the future of dementia research and the key shifts that could redefine clinical trials and patient care in neurodegenerative diseases: #DementiaResearch #CNSDrugDevelopment #ClinicalTrials #Innovation #FutureofMedicine

The selection of the right cognitive assessment isn't just a methodological choice; it's a foundational element that underpins the reliability and impact of your clinical trial data. ➡️ Explore the factors to consider and the benefits of each approach:

AD/PD kicks off today with a packed agenda! .🥇Get our posters delivered to your inbox here:

New Mild Cognitive Impairment insights! 💡. Nick Taptiklis's #ADPD2025 poster reveals novel reaction time measures from CANTAB® PAL. Discover how timing-based data enhances understanding of MCI. Download now! ➡️ .#MCI #Neuroscience #Alzheimers #Parkinsons

The ability to conduct reliable cognitive testing remotely is crucial for expanding access and efficiency in studies related to aging and neurodegenerative diseases. Get the poster here! #Alzheimers #Parkinsons #ClinicalTrials #Neuroscience

Join our Chief Scientist for her poster "Novel Digital Measures of Reaction Time and Drawing Speed" from the @ideafastproject. Discover how our digital tools can provide unique insights into movement & accuracy in neurodegenerative disorders:

Does computerised cognitive testing have sufficient sensitivity for assessing cognitive impairment associated with #schizophrenia in clinical trials? . Get the research: #SIRS2025 #SchizophreniaResearch #ClinicalTrials #DigitalHealth

Can speech reveal the severity of #schizophrenia symptoms? Find out more:

With DiMe’s DATAcc ADRD project, we’ve confirmed that visuospatial memory and expressive communication are critical for understanding ADRD progression. Read more: #Alzheimers #Dementias #Neuroscience #ClinicalTrials